Prescription and Adverse drug effects analysis in Paediatric Acute Lymphoid Leukaemia .
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]
- Registration Number
- CTRI/2021/09/036279
- Lead Sponsor
- Dr Gaurav Narula Professor Medical Oncology Pediatrics Unit
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
a)Patients of either gender and age between 1-15 years treated with one cycle in induction phase (On going or completed consolidation and maintenance phase also included).
b)Parent/Legally Acceptable Representative (LAR) of the patient willing to give voluntary informed consent.
c)Patient above 8 years willing to give voluntary assent
Exclusion Criteria
1.Any other medical condition, which in the opinion of the investigator precludes the inclusion of the participant.
2.Critically ill patients of Acute lymphoblastic Leukaemia admitted to emergency department
3.Newly diagnosed and treatment naïve patients.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Drugs prescribed in treatment of Acute Lymphoblastic Leukaemia patientsTimepoint: 18 months
- Secondary Outcome Measures
Name Time Method The type, causality, severity and preventability of ADRs in Acute Lymphoblastic Leukaemia. <br/ ><br> <br/ ><br>Timepoint: 18 months;To evaluate the Cost of Illness in Acute Lymphoblastic Leukaemia. <br/ ><br> <br/ ><br>Timepoint: 18 months